Bristol Myers Squibb (BMY) financial statements
- FY2025 revenue
- $48.2B▼ −0.2%
- FY2025 net income
- $7.1B
- FY2025 diluted EPS
- $3.46
- FY2025 free cash flow
- $12.8B▼ −7.9%
Bristol Myers Squibb income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 48,194 | 48,300 | 45,006 |
| Pretax income | 9,328 | -8,379 | 8,440 |
| Net income | 7,054 | -8,948 | 8,025 |
| Diluted earnings per share | 3.46 | -4.41 | 3.86 |
Bristol Myers Squibb balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 10,209 | 10,347 | 11,519 |
| Total assets | 90,038 | 92,603 | 95,159 |
| Total liabilities | 71,533 | 76,215 | 65,674 |
| Total equity | 18,506 | 16,388 | 29,485 |
| Long-term debt | 42,850 | 47,603 | 36,653 |
Bristol Myers Squibb cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 14,156 | 15,190 | 13,860 |
| Capital expenditure | -1,311 | -1,248 | -1,209 |
| Free cash flow (derived) | 12,845 | 13,942 | 12,651 |
| Dividends paid | -5,045 | -4,863 | -4,744 |
| Share repurchases | 0 | 0 | -5,155 |
Quarterly highlights
| USD millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue (derived) | 13,069 | 12,973 | 11,489 | 12,502 |
| Net income (derived) | 2,162 | 3,317 | 2,677 | 1,087 |
| Diluted earnings per share | 1.05 | 1.62 | 1.31 | n/a |
| Operating cash flow (derived) | 4,181 | 3,393 | 1,104 | 1,974 |
| Total assets | 88,772 | 87,634 | 86,476 | 90,038 |
Bristol Myers Squibb major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| Vanguard Capital Management | 7.5% | 153,108,018 | 30 April 2026 |
| BlackRock, Inc. | 7.1% | 143,574,230 | 17 April 2025 |
| STATE STREET CORPORATION | 5.0% | 102,521,748 | 7 August 2026 |
Bristol Myers Squibb 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 29 October 2026 | 10-Q | Quarterly report | Quarterly report |
| 29 October 2026 | 8-K | Current report | Current report |
| 30 July 2026 | 10-Q | Quarterly report | Quarterly report |
| 30 July 2026 | 8-K | Current report | Current report |
| 8 May 2026 | 8-K | Current report | CURRENT REPORT |
| 30 April 2026 | 10-Q | Quarterly report | Quarterly report |
| 30 April 2026 | 8-K | Current report | Current report |
| 11 February 2026 | 10-K | Annual report | Annual report |
Common questions
What was Bristol Myers Squibb's revenue in fiscal 2025?
Bristol Myers Squibb reported $48.2 billion in revenue for fiscal 2025, the year ended 31 December 2025, down 0.2% from fiscal 2024.
What was Bristol Myers Squibb's net income in fiscal 2025?
Bristol Myers Squibb reported net income of $7.1 billion for fiscal 2025, the year ended 31 December 2025. Diluted earnings per share were $3.46.
What was Bristol Myers Squibb's free cash flow in fiscal 2025?
Bristol Myers Squibb had $12.8 billion in free cash flow in fiscal 2025. Operating cash flow was $14.2 billion and capital expenditure was $1.3 billion.
What were Bristol Myers Squibb's total assets at the end of fiscal 2025?
Bristol Myers Squibb reported total assets of $90.0 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much Bristol Myers Squibb history does each plan include?
Free covers the last 3 fiscal years of annual figures. Basic covers the last 10 fiscal years, annual and quarterly. Pro covers the full history, with first reported values and as of dates.
Get these figures through the API
5,000 free requests every month. No card needed.